Wednesday, July 8, 2026

Patent intelligence · US

US 10729768

Combination of anti-CD20 antibody and PI3 kinase selective inhibitor

granted A61KA61K31/519A61K39/3955A61K45/06
Status granted
Linked drugs 3
Pipeline programs 6
Years to expiry 14
Applicant portfolio 7
Patent details — US 10729768
Jurisdiction
US
Status
granted
Grant date
Aug 4, 2020
Expiration
Jul 30, 2040
Claims
35
CPC classes
A61K, A61K31/519, A61K39/3955, A61K45/06
View on Google Patents ↗

Quick answer

US 10729768 (Combination of anti-CD20 antibody and PI3 kinase selective inhibitor) is held by TG Therapeutics, Inc.. Status: granted. Granted Aug 4, 2020. Expires Jul 30, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
35
CPC classes
A61K, A61K31/519, A61K39/3955, A61K45/06, A61P, A61P37/00

More from TG Therapeutics, Inc.

Related pharmaceutical patents in our USPTO index.

  1. US 11965032

    Anti-CD20 antibody compositions

    TG Therapeutics, Inc. · Expires Apr 18, 2044

    granted
  2. US 11884740

    Anti-CD20 antibody compositions

    TG Therapeutics, Inc. · Expires Jan 25, 2044

    granted
  3. US 11814439

    Anti-CD20 antibody compositions

    TG Therapeutics, Inc. · Expires Nov 9, 2043

    granted
  4. US 11807689

    Anti-CD20 antibody compositions

    TG Therapeutics, Inc. · Expires Nov 2, 2043

    granted
  5. US 10966977

    Combination of anti-CD20 antibody, P13 kinase-delta selective inhibitor, and BTK inhibitor to treat b-cell proliferative disorders

    TG Therapeutics, Inc. · Expires Apr 1, 2041

    granted
  6. US 9694071

    Combination of anti-CD20 antibody and PI3 kinase selective inhibitor

    TG Therapeutics, Inc. · Expires Jun 29, 2037

    granted

Frequently asked questions

What is US patent 10729768?

US 10729768 (Combination of anti-CD20 antibody and PI3 kinase selective inhibitor) is held by TG Therapeutics, Inc.. Status: granted. Granted Aug 4, 2020. Expires Jul 30, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 10729768?

TG Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 7 pharmaceutical patents for this assignee.

When does US 10729768 expire?

Our index shows an expiration date of Jul 30, 2040 (14 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.